Zenas BioPharma, Inc. (Nasdaq: ZBIO) announced its financial results for the fourth quarter and full year ended December 31, 2025, highlighting significant progress in its clinical pipeline. The company reported a revenue of $10 million for the year, primarily from a licensing agreement with Zai Lab for its thyroid eye disease program. However, Zenas also reported a net loss of $377.7 million for the year, reflecting increased research and development expenses, particularly related to its lead product candidate, obexelimab.

The company is preparing to submit marketing applications for obexelimab for the treatment of IgG4-related disease (IgG4-RD) to the FDA in Q2 2026 and to the EMA in H2 2026, based on positive results from the Phase 3 INDIGO trial. Additionally, Zenas is advancing its pipeline with several promising candidates, including orelabrutinib for multiple sclerosis and ZB021, an oral IL-17AA/AF inhibitor expected to enter clinical trials in 2Q 2026.

Zenas has also secured a non-dilutive, multi-tranche debt financing arrangement of up to $250 million from Pharmakon Advisors, which will provide the necessary capital to support its operational needs and pipeline development. This financing is expected to enhance Zenas's financial flexibility as it moves towards commercialization of its lead candidates.

Overall, the company’s strategic focus on advancing its pipeline and securing funding positions it well for future growth, despite the current financial losses. Investors will be keenly watching the upcoming regulatory submissions and trial results, which could significantly impact the company's valuation and market position.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.